Special Issue "Immunomodulatory Compounds"
Deadline for manuscript submissions: 30 June 2018
Nature has developed, during evolution, a broad variety of immunomodulatory compounds, e.g., to facilitate invasion and/or persistence of pathogens and parasites. The characterization of these compounds have provided new insights into immunology, parasitology and various diseases, such as autoimmune diseases. The development of chemical analogues of these naturally-occurring compounds has opened a new field of drug development and medical therapy.
The scope of this Special Issue is to give an overview of this field, comprising the detection and characterization of naturally-occurring immunomodulatory compounds, their application in medicine and veterinary medicine, and the development of chemical analogues and their therapeutic perspectives.
Prof. Dr. Günter Lochnit
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- autoimmune diseases
- hepatic targeting
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Tentative title: Effect of the ArtinM lectin in the IL-17 production by B cells
Authors: Patrícia Kellen Oliveira-Brito, Maria Cristina Roque-Barreira, Thiago A da Silva
Affiliations: University of São Paulo-FMRP; Ribeirão Preto, São Paulo, Brazil
Authors: Katrin Richter1,*, Christian Koch1,*, Elke K.H. Schweda2, Sven Wichmann1, Sigrid Wilker1, Ilona Magel1, Michael Sander1, J. Michael McIntosh3, Winfried Padberg1, Veronika Grau1
Affiliations: 1Justus-Liebig University, Giessen, Germany; 2Linköping University, Linköping, Sweden; 3University of Utah, Salt Lake City, Utah, USA
Abstract: Phosphocholine (PC)-modified cell wall components of Gram-negative and Gram-positive bacteria are known virulence factors that enable immune evasion and permanent colonization of the mammalian host, via mechanisms that are poorly understood. Recently, our group demonstrated that high concentrations of free PC as well as PC-modified lipooligosaccharides from Haemophilus influenzae function as unconventional nicotinic agonists and efficiently inhibit the ATP-induced release of monocytic IL-1β. This pro-inflammatory cytokine plays a central role in host defense against bacteria. Here, we test the hypothesis that H. influenzae lipooligosaccharides exert similar effect on pulmonary epithelial cells.
The human adenocarcinoma-derived cell lines A549 and Calu-3 were primed with lipopolysaccharide from Echerichia coli followed by stimulation with ATP in the presence or absence of PC or PC-modified H. influenzae lipooligosaccharides. As a negative control, we included lipooligosaccharides devoid of PC that were purified from corresponding H. influenzae lic1 mutants. The involvement of nicotinic acetylcholine receptors was tested using specific nicotinic antagonists.